Keizo Koya, Senior VP, Drug Development at SYNTA PHARMACEUTICALS CORP (SNTA), bought 10,000 shares at $2.84 ($28K) on 2009-08-24, disclosed to the SEC on 2009-08-26.
Open-market purchase of $28k SNTA by Senior VP, Drug Development. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history).
Something here stands out, but not much.
| Filing → |
| SNTA | SELL | 2011-03-03 | $96K | — | Filing → |